Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure

Rehman, Shafiq; Mueller, Thomas; Januzzi, James L.

doi:10.1016/j.jacc.2008.07.042

Cited by 354 publications

(267 citation statements)

References 33 publications

Supporting

Mentioning

209

Contrasting

Unclassified

Order By: Relevance

“…When heart perceives stress, their serum levels begin to rise and their random variations are high. Thus their role of monitoring heart failure prognosis may be unsatisfactory for physicians who need timely responses (Willems et al 2013, Rehman et al 2008). …”

Section: Backgroundsmentioning

confidence: 99%

“…Soluble ST2 can reflect the process of cardiac remodeling and myocardial post-injury fibrosis in heart failure (Rehman et al 2008, Schmitz et al 2005, Moore and Januzzi 2010, and so it has much less confounding than conventional BNP/NT-proBNP (Mueller and Dieplinger 2013). When ST2 serum levels climb, it means there is considerable myocardial damage (Broch et al 2012, Lupón et al 2013.…”

Section: Backgroundsmentioning

confidence: 99%

“…In addition ACCF/AHA has proposed the 2013 Guideline for the Management of Heart Failure that includes ST2 in the recommendations (Yancy et al 2013). ST2 and NT-proBNP can work together for better sensitivity and specificity (Pascual-Figal et al 2011a, Sabatine et al 2008.…”

Section: Backgroundsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical roles of soluble ST2 for the outcomes of cardiac valve operations

Chen¹

2016

RIO

View full text Add to dashboard Cite

Executive summarySoluble ST2 is a novel cardiac biomarker that reflects cardiac injury and the response to treatment. Previous studies showed that ST2 has less confounding and more specific than NT-proBNP. ACCF/AHA has proposed 2013 Guidelines for the Management of Heart Failure that includes ST2 in the recommendations. In the research proposal, we will assess the clinical role of serum ST2 level in cardiac non-coronary valve surgical patients.We will recruit 70 patients who undergo cardiac non-coronary valve operations. Serum levels of ST2 and NT-proBNP and troponin-T will be measured at preoperative baseline, postoperative 24 hours, and postoperative 5 to 10 days in the routine blood sampling. The endpoints include hospital mortality, all-cause mortality, unexpected ICU return, MACE, time to extubation, and total length of stay. We will also collect various preoperative, operative, and postoperative variables, such as EuroScore-II. Their relationships will be analyzed.We expect to demonstrate the superior role of ST2 to NT-proBNP and other variables in risk stratification and outcome prediction and assessment in our cohort. ‡, §

show abstract

Section: Backgroundsmentioning

confidence: 99%

Section: Backgroundsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical roles of soluble ST2 for the outcomes of cardiac valve operations

Chen¹

2016

RIO

View full text Add to dashboard Cite

show abstract

“…Given NT‐proBNP's strong associations with heart failure, mortality attributable to cardiovascular events, and mortality after cardiac surgery, its inclusion in a prediction model of in‐hospital mortality may serve to improve the model's predictive ability 13, 14, 15, 16. Galectin‐3, a member of the lectin family of proteins, and ST2, a biomarker for cardiac stress, have also been found to be strongly associated with heart failure 17, 18, 19, 20, 21, 22. Additionally, Galectin‐3 has been found to be associated with increased risk for all‐cause mortality in the Framingham Offspring Cohort 23.…”

Section: Introductionmentioning

confidence: 99%

Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin‐3, and NT‐ProBNP Before Cardiac Surgery

Polineni

Parker

Alam

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundCurrent preoperative models use clinical risk factors alone in estimating risk of in‐hospital mortality following cardiac surgery. However, novel biomarkers now exist to potentially improve preoperative prediction models. An assessment of Galectin‐3, N‐terminal pro b‐type natriuretic peptide (NT‐ProBNP), and soluble ST2 to improve the predictive ability of an existing prediction model of in‐hospital mortality may improve our capacity to risk‐stratify patients before surgery.Methods and ResultsWe measured preoperative biomarkers in the NNECDSG (Northern New England Cardiovascular Disease Study Group), a prospective cohort of 1554 patients undergoing coronary artery bypass graft surgery. Exposures of interest were preoperative levels of galectin‐3, NT‐ProBNP, and ST2. In‐hospital mortality and adverse events occurring after coronary artery bypass graft were the outcomes. After adjustment, NT‐ProBNP and ST2 showed a statistically significant association with both their median and third tercile categories with NT‐ProBNP odds ratios of 2.89 (95% confidence interval [CI]: 1.04–8.05) and 5.43 (95% CI: 1.21–24.44) and ST2 odds ratios of 3.96 (95% CI: 1.60–9.82) and 3.21 (95% CI: 1.17–8.80), respectively. The model receiver operating characteristic score of the base prediction model (0.80 [95% CI: 0.72–0.89]) varied significantly from the new multi‐marker model (0.85 [95% CI: 0.79–0.91]). Compared with the Northern New England (NNE) model alone, the full prediction model with biomarkers NT‐proBNP and ST2 shows significant improvement in model classification of in‐hospital mortality.ConclusionsThis study demonstrates a significant improvement of preoperative prediction of in‐hospital mortality in patients undergoing coronary artery bypass graft and suggests that biomarkers can be used to identify patients at higher risk.

show abstract

“…There have been several papers suggesting the usefulness of sST2 in predicting adverse outcomes, but the relationship between a single measurement of sST2 protein and the necessity of hospitalization in CHF still remains unknown. [7][8][9][10][11][12][13][14][15][16][17][18][19][20] The aim of this study was to determine the association between a single measurement of sST2 concentration and hospitalizations due to worsening CHF in a 1-year follow-up period.…”

mentioning

confidence: 99%

Soluble ST2 protein and hospitalizations due to worsening chronic heart failure during a one-year follow-up in a population with reduced ejection fraction

Wojtczak-Soska¹,

Sakowicz²,

Pietrucha³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure

Abstract: Consistent with its proposed role in a myocardial-specific response to stretch, ST2 has strong clinical and biochemical correlates in patients with acute HF. Prognostically, ST2 is powerful in acute HF and is synergistic with natriuretic peptides for this use.

Cited by 354 publications

References 33 publications

Clinical roles of soluble ST2 for the outcomes of cardiac valve operations

Clinical roles of soluble ST2 for the outcomes of cardiac valve operations

Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin‐3, and NT‐ProBNP Before Cardiac Surgery

Soluble ST2 protein and hospitalizations due to worsening chronic heart failure during a one-year follow-up in a population with reduced ejection fraction

Contact Info

Product

Resources

About